Spexis is Granted Debt-Restructuring Moratorium

Spexis AG / Key word(s): Miscellaneous
Spexis is Granted Debt-Restructuring Moratorium

05-Dec-2023 / 07:15 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement pursuant to Art. 53 LR

Spexis is Granted Debt-Restructuring Moratorium

Allschwil, Switzerland, December 5, 2023

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on
macrocycle therapeutics for rare diseases and oncology, today announced that
it has been formally granted moratorium status (Nachlassstundung) by the
Western District Court of the Canton Basel-Landschaft. This announcement
follows the Company's announcement of November 29th indicating that a formal
request for such status had been submitted.

The plan submitted to the court included a cost reduction, a restructuring
of the debt with major secured and unsecured creditors (such as SPRIM Global
Investments), a continuation of the COPILOT trial in case additional
financing can be obtained and a sale of other assets. All of these
initiatives are being implemented by Spexis.

The Company will issue further milestone announcements as parts of its
moratorium plan are achieved.

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in
Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases
and oncology. For further information please visit: www.spexisbio.com.

For further information please contact:

For Investors:

     Stephen Jasper
     Managing Director
     Gilmartin Group
     (1)stephen@gilmartinir.com

For Media:

     Dr. Stephan Feldhaus
     Feldhaus & Partner
     +41 79 865 92 56
     (2)feldhaus@feldhaus-partner.ch

     1. mailto:stephen@gilmartinir.com
     2. mailto:feldhaus@feldhaus-partner.ch

Disclaimer

This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


---------------------------------------------------------------------------

End of Inside Information

---------------------------------------------------------------------------

   Language:       English
   Company:        Spexis AG
                   Hegenheimermattweg 125
                   4123 Allschwil
                   Switzerland
   Phone:          +41 61 567 1600
   Fax:            +41 61 567 1601
   E-mail:         info@spexisbio.com
   Internet:       www.spexisbio.com
   ISIN:           CH0106213793
   Valor:          SPEX
   Listed:         SIX Swiss Exchange
   EQS News ID:    1789023

End of Announcement EQS News Service
---------------------------------------------------------------------------

1789023 05-Dec-2023 CET/CEST